David Epstein Sells 250 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 250 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $75.55, for a total value of $18,887.50. Following the completion of the sale, the director owned 26,421 shares of the company’s stock, valued at $1,996,106.55. The trade was a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Tempus AI Stock Up 1.9%

Shares of TEM opened at $76.33 on Friday. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $13.58 billion, a PE ratio of -64.14 and a beta of 4.99. The stock’s 50-day moving average price is $82.12 and its two-hundred day moving average price is $72.84.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. During the same period in the prior year, the business posted ($0.46) earnings per share. The firm’s revenue was up 84.7% on a year-over-year basis. On average, analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current year.

Institutional Investors Weigh In On Tempus AI

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Tempus AI by 6,247.5% in the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock worth $289,204,000 after purchasing an additional 5,900,668 shares during the last quarter. Jump Financial LLC purchased a new stake in Tempus AI in the first quarter worth about $8,545,000. Tyler Stone Wealth Management purchased a new stake in shares of Tempus AI in the 1st quarter worth approximately $386,000. Salem Investment Counselors Inc. increased its stake in Tempus AI by 8,020.0% during the 2nd quarter. Salem Investment Counselors Inc. now owns 30,450 shares of the company’s stock valued at $1,935,000 after purchasing an additional 30,075 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Tempus AI during the first quarter valued at approximately $260,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TEM. Morgan Stanley lifted their target price on Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday. Canaccord Genuity Group dropped their price objective on shares of Tempus AI from $110.00 to $95.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. Needham & Company LLC raised their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Cowen cut Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $81.17.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.